Aprismo

Aprismo is a brand name for a medication containing the active ingredient brentuximab vedotin. It is a type of targeted therapy used in the treatment of certain types of lymphoma, a cancer of the lymphatic system. Specifically, Aprismo is approved for adult patients with Hodgkin lymphoma that has relapsed or is refractory after at least two prior treatment regimens, and for adult patients with systemic anaplastic large cell lymphoma (ALCL) that is relapsed or refractory after at least one prior chemotherapy regimen.

Brentuximab vedotin is a conjugate drug, meaning it combines a monoclonal antibody with a cytotoxic agent. The monoclonal antibody component targets a protein called CD30, which is found on the surface of lymphoma cells. Once attached to the CD30 protein, the drug is internalized by the cancer cell, releasing the cytotoxic agent, which then damages and kills the cell. This targeted approach aims to minimize damage to healthy cells, thereby reducing some of the side effects associated with traditional chemotherapy.

Aprismo is administered intravenously. The dosage and schedule of administration are determined by a healthcare professional based on the patient's specific condition and response to treatment. Common side effects may include peripheral neuropathy, fatigue, nausea, diarrhea, fever, and rash. It is important for patients to discuss any potential side effects or concerns with their doctor. Aprismo is manufactured by Seagen Inc. and Takeda Pharmaceutical Company.